Introduction {#s1}
============

*Toxoplasma gondii* is the leading infectious cause of posterior uveitis worldwide and may result in significant morbidity and vision loss, particularly if there is a delay in diagnosis and treatment.[@R1] Ocular toxoplasmosis may occur in the setting of congenital or otherwise distant *T. gondii* infection, but may also present following primary infection.[@R3] Ordinarily, fundus examination alone is sufficient to establish the diagnosis of ocular toxoplasmosis. When clinical presentation is atypical, particularly in immunocompromised patients, or when the fundus is not well visualised due to dense vitritis or other opacities, or in cases refractive to anti-*toxoplasma* therapy, laboratory testing of intraocular fluid samples is indicated to confirm the presence of *T. gondii* DNA and rule out other infectious causes.

Molecular testing for *T. gondii* DNA relies on the detection of two conserved multicopy sequences present in the *T. gondii* genome; the B1 gene (30--35 copies/genome) and the Rep529 repetitive elements (200--300 copies/genome).[@R5] While anterior chamber paracentesis and vitreous tap can be routinely done in the clinic to obtain intraocular fluid for testing, they are not without the potential for procedure-associated complications (eg, corneal endothelium or lens injury, intraocular haemorrhage, retinal detachment and endophthalmitis). Coupled with the low sample volumes that can be safely obtained from the patient, it is highly desirable to have the selection of an assay target with the best diagnostic performance. Due to a higher genomic copy number, analytical and clinical sensitivity for assays targeting Rep529 appear to be superior to B1 assays; however, few ocular samples have been included in these studies.[@R5] To date, direct comparisons assessing the diagnostic performance of PCR assays targeting B1 and Rep529 targets in ocular samples from US patients, where different *T. gondii* strains are prevalent,[@R8] have not been performed. Herein, we describe the analytical characteristics of a single-reaction, internally controlled, B1-Rep529 dual-target, real-time PCR assay and evaluate the clinical performance of this assay on intraocular fluid samples collected at the Francis I. Proctor Foundation, a tertiary centre for ophthalmologic care in the USA.

Methods {#s2}
=======

Study design {#s2-1}
------------

One hundred and forty-eight archived intraocular samples (132 vitreous fluid, 16 aqueous humour) previously tested for *T. gondii* DNA at the Francis I. Proctor Foundation were selected for evaluation. The samples were archived between January 2010 and December 2015, boiled, and then stored at −80°C. The samples were deidentified using standard institutional procedures and randomised. All laboratory personnel were masked to the reference results until all analyses were completed.

Lower limit of detection {#s2-2}
------------------------

Partially purified *T. gondii* strain Z185 culture fluid from propagation in MRC-5 fibroblast cells was purchased from Zeptometrix (Buffalo, New York, USA). The tachyzoites were quantitated using a Petroff-Hausser Counting Chamber, and the stock concentration determined to be 6.6×10^6^ tachyzoites/mL. The 95% lower limit of detection (LLOD) was calculated by probit analysis using the Generalized Linear Models (glm) function from stats package (V.3.3.1) in R.[@R9]

*T. gondii* single-reaction, internally-controlled, dual-target, real-time PCR assay {#s2-3}
------------------------------------------------------------------------------------

Total nucleic acids were extracted from 50 µL culture supernatant dilutions or up to 50 µL of each clinical specimen on the BioRobot EZ1 (Qiagen, Germantown, Maryland, USA) using the EZ1 virus mini kit 2.0 according to the manufacturer's recommendations. The sample volume was made up to 200 µL with nuclease-free water and eluted in 60 µL buffer AVE containing cRNA. Internal control (IC) DNA template was supplied at this step which is spiked in and extracted by the instrument.

This PCR assay targets both B1 and Rep529 ([figure 1A](#F1){ref-type="fig"}) using primers and probes described previously.[@R10] Primers (Rep529_F: 5'-AGAGACACCGGAATGCGATCT-3'; Rep529_R: 5'-TTCGTCCAAGCCTCCGACT-3'; B1_F: 5'-GAAAGCCATGAGGCACTCCA-3'; B1_R: 5'-TTCACCCGGACCGTTTAGC-3') were purchased from Integrated DNA Technologies (San Diego, California, USA) and hydrolysis probes (Rep529 probe: 5'-FAM-TCGTGGTGATGGCGGAGAGAATTGA-BHQ1-3'; B1 Probe: 5'-Quasar 705-CGGGCGAGTAGCACCTGAGGAGATACA-BHQ2-3') were purchased from Biosearch Technologies (Petaluma, California, USA). Real-time PCR was performed using the Quantifast Pathogen +IC kit on the Rotor-Gene Q instrument (both from Qiagen, Germantown, Maryland, USA). Primers and probes were added in a single reaction at final concentrations of 400 nM and 200 nM, respectively. Ten µL of eluate was added in a final reaction volume of 25 µL. The Quantifast Pathogen +IC master mix also contains a primer/probe set targeting the IC DNA. Cycling conditions are as follows: hold at 95°C for 5 min, then 45 cycles of 95°C for 15 s and 60°C for 30 s. Detection was performed in the green (Rep529), crimson (B1) and yellow (IC) channels; the threshold was set at 0.05 for all three channels. Any amplification curve crossing this threshold in green or crimson channels was considered positive for *T. gondii*. Samples were considered to have failed extraction or contain inhibitory substances if the IC did not amplify in samples negative for *T. gondii*.

![Comparison of dual-target *T*oxoplasma* gondii* multiplex, real-time PCR and B1 *T. gondii* nested PCR. (A) The dual-target assay uses fluorescently labelled hydrolysis probes targeting B1 (crimson) and Rep529 (green) as well as an internal control (yellow). This design allows amplification and fluorescence detection of both B1 and Rep529 in a single, real-time PCR reaction. (B) The nested B1 PCR assay relies on sequential conventional PCR reactions using outer primers in the first reaction and inner primers in the second reaction. The final PCR product is detected by agarose gel electrophoresis and ethidium bromide staining.](bjophthalmol-2018-313064f01){#F1}

Reference testing {#s2-4}
-----------------

Nested, conventional PCR targeting the B1 gene ([figure 1B](#F1){ref-type="fig"}) was performed at the Francis I. Proctor Foundation CLIA-accredited microbiology laboratory as part of routine clinical testing. Briefly, intraocular fluid samples were boiled for 10 min and 4 µL of the boiled aqueous or vitreous fluid was subjected to 2 rounds of PCR with the following primers targeting the B1 gene: 5F_external: GGA ACT GCA TCC GTT CAT GAG; 5R_external: TCT TTA AAG CGT TCG TGG TC; 5F_internal: TGC ATA GGT TGC AGT CAC TG; 5R_internal: GGC GAC CAA TCT GCG AAT ACA CC. Both PCR assays used 5 µL of 10X PCR buffer (Sigma-Aldrich, St. Louis, Missouri, USA), 1.5 *m*M of MgCl~2~, 0.1 *m*M dNTP mix, 10 pmol of each primer and 0.05 U of REDTaq DNA polymerase (Sigma-Aldrich) in a total reaction volume of 50 µL. Amplified products were evaluated on 4% e-Gels (Thermo Fisher Scientific, Waltham, Massachusetts, USA). This assay has a LLOD of 5 tachyzoites/mL (unpublished, F. I. Proctor Foundation).

Samples in which the nested PCR and dual-target, real-time PCR results were discrepant, were tested by B1 real-time PCR at the Palo Alto Medical Foundation Toxoplasmosis Serology Laboratory (PAMF-TSL), the US National Toxoplasmosis Reference Laboratory.

Results {#s3}
=======

The 95% LLOD of dual-target assay was determined to be 1.05 tachyzoites/mL for B1 and 0.83 tachyzoites/mL for Rep529. A set of 148 intraocular specimens, 132 vitreous and 16 aqueous samples, collected from patients with suspected intraocular *T. gondii* infection were then tested by the dual-target assay. Appropriate amplification of the IC in all samples revealed adequate extraction and the absence of inhibitors. Compared with the reference nested B1 PCR performed at the F.I. Proctor Foundation, the dual-target assay demonstrated 97.2% positive agreement (n=35/36; 95% CI 83.7% to 99.9%) and 99.1% negative agreement (n=111/112; 95% CI 94.4% to 100%) ([table 1](#T1){ref-type="table"}). There were 35 samples with detectable *T. gondii* DNA in both assays, and in all of these samples, both the B1 and Rep529 targets were detected in the dual-target assay. The cycle threshold value was on average 0.75 cycles later in the crimson channel (B1) compared with the green channel (Rep529) (p=0.0019, 95% CI 0.30 to 1.20; paired t-test).

###### 

Comparison of *Toxoplasma gondii* DNA detection in the B1-Rep529 dual-target, real-time PCR assay and the nested, conventional B1 PCR performed at the Francis I. Proctor Foundation

                                    Nested B1 PCR   Total         
  --------------------------------- --------------- ------- ----- -----
  **B1-Rep529** **real-time PCR**   Positive        35      1     36
  Negative                          1               111     112   
                                    Total           36      112   148

There were two discrepant samples; one dual-target negative, nested B1 positive and the other dual-target positive (Rep529 only; crossing threshold (Ct) value=39.14), nested B1 negative. Reference testing at the PAMF-TSL demonstrated that both specimens were negative for *T. gondii* DNA using B1 real-time PCR.

Discussion {#s4}
==========

We present here the analytical and clinical evaluation of a single-reaction, internally controlled, B1-Rep529 dual-target *T. gondii* real-time PCR assay for the diagnosis of ocular toxoplasmosis. As expected, the Rep529 component of this assay was more analytically sensitive than the B1 component, as has been demonstrated in several manuscripts comparing B1 and Rep529 single-target assays.[@R11] We also observed excellent overall agreement of the dual-target assay compared with conventional, nested B1 PCR when used to test intraocular specimens from patients with suspected ocular toxoplasmosis.

This study comparatively evaluates the diagnostic performance of the dual-target *T. gondii*-PCR assay on intraocular samples from US patients ([table 2](#T2){ref-type="table"}). In Europe, assays targeting Rep529 have largely replaced assays targeting B1 due to higher genome copy numbers (200--300 copies/genome vs 30--35 copies/genome) and overall higher clinical sensitivity in numerous specimen types, including amniotic fluid, placental tissue, cord blood, cerebrospinal fluid and peripheral blood. However, few studies have directly compared B1 and Rep529 PCR assays on intraocular specimens. A literature review performed in PubMed of studies published in the English language identified only four such studies, three conducted in France and one in Brazil ([table 2](#T2){ref-type="table"}).[@R10] Though these studies used various reference methods and included a wide range of sample sizes, Rep529 DNA was generally detected in more cases than B1 DNA. Our study included one B1 negative/Rep529 positive case (Ct value=39.14); a false negative B1 case was also reported by Belaz *et al* in an intraocular specimen with a late Rep529 Ct value.[@R13] These findings suggest that low parasite loads, which can occur in the setting of prior anti-*toxoplasma* therapy, may account for these B1 negative/Rep529 positive cases. Consistent with this hypothesis, several studies of congenital toxoplasmosis in France, where anti-*toxoplasma* therapy is offered throughout pregnancy, have demonstrated lower diagnostic sensitivity of B1 PCR assays in amniotic fluid samples.[@R17] Consequently, exposure to anti-*toxoplasma* therapy in ocular toxoplasmosis may have the same deleterious effect on the diagnostic yield of intraocular *T. gondii* PCR if tested using a B1-only assay.

###### 

Studies evaluating real-time PCR assays for detection of *Toxoplasma gondii* DNA in intraocular samples using the B1 gene and Rep529 targets

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                  Year   Country   Single-reaction   Internally controlled   Sample size   Type of fluid   Sensitivity n/N (%)   Specificity\      Reference test                     
                                                                                                                                         (%)                                                  
  ----------------------- ------ --------- ----------------- ----------------------- ------------- --------------- --------------------- ----------------- ---------------- ----------------- ------------------------------------------------------------------------------------
  Cassaing[@R15]          2006   France    No                No                      3             AH:3            3/3 (100%)            3/3 (100%)        NA               NA                Rep529 real-time PCR

  Fekkar *et al* [@R10]   2008   France    No                Yes                     110           AH:92; VF: 18   9/34 (26.5%)          13/34 (38.2%)     76/76 (100%)     76/76 (100%)      Ophthalmological examination

  Belaz *et al* [@R13]    2015   France    No                Yes                     6             AH:5;\          5/6 (83.3%)           6/6 (100%)        NA               NA                Western blot
                                                                                                   VF:1                                                                                       

  Santos *et al* [@R16]   2015   Brazil    No                Yes                     43            AH:43           16/43 (100%)          16/43 (100%)      NA               NA                Fundoscopic examination compatible with active focal necrotizing retinochoroiditis

  Gomez                   CR     USA       Yes               Yes                     148           AH:16; VF:132   35\*/36 (97.2%)       35\*/36 (97.2%)   112/112 (100%)   111\*/112 (99%)   Conventional nested B1 PCR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*There were two discrepant samples; one dual-target negative, nested B1 positive, and the other dual-target positive (Rep529 only; Ct value=39.14), nested B1 negative. Reference testing at the Palo Alto Medical Foundation Toxoplasmosis Serology Laboratory revealed that both specimens were negative for *T. gondii* DNA using B1 real-time PCR.

AH, aqueous humour; CR, current report; NA, not available; VF, vitreous fluid.

In contrast to the previous studies investigating *T. gondii* PCR targets in intraocular fluids, the assay described herein combines B1, Rep529 and an IC in a single reaction. Nevertheless, our data, as well as the studies presented in [table 2](#T2){ref-type="table"}, support the implementation of a diagnostic assay that targets only Rep529. However, this single-reaction, dual-target approach is frequently applied in molecular diagnostics for viral infections, such as HIV-1 and HBV, to reduce the chance of false-negative results due to mutations that disrupt primer/probe binding. The utility of an assay that includes both B1 and Rep529 targets in a single tube, is supported by a report from East Africa in which 5% of clinical samples demonstrated Rep529 amplification failures.[@R19] Similarly, a study of amniotic fluid specimens collected in Brazil demonstrated a lower proportion of positive results detected by the Rep529 target (36.5%) compared with the B1 target (87.3%) with only 24% of samples being positive for both targets.[@R20] In our US cohort, however, we did not identify any dual-target-assay-positive intraocular samples in which only the B1 target was detected. Nonetheless, as ocular toxoplasmosis frequently emerges from congenital or postnatally acquired *T. gondii* infections, diagnosis of B1 positive/Rep529 negative ocular toxoplasmosis may be particularly important in patients born outside of the USA and in returning travellers. In addition, some *T. gondii* strains may contain fewer copies of Rep529 than previously estimated,[@R21] further supporting the inclusion of both targets to optimise *T. gondii* DNA detection.

Limitations of this study include its retrospective design, and the absence of clinical, serological and epidemiological data, to correlate with molecular target detection. Factors such as the presence or length of anti-*toxoplasma* therapy, the timing between the onset of clinical symptoms and ocular fluid sampling, as well as severity and rates of relapse, were not investigated, though these variables may explain the overall similar performance of the two targets. In addition, immunodiagnostic methods, such as the Goldmann-Witmer coefficient and Western blotting, which may be complementary to nucleic acid amplification testing, were not performed. Finally, typing and genomic characterisation of the *T. gondii* strains causing ocular toxoplasmosis in the USA were beyond the scope of this study, particularly in the context of type-specific associations with severe disease and higher rates of recurrences.[@R22] Comparison of these strains with *T. gondii* genomes from other parts of the world may yield a better understanding of the pathogenesis of ocular toxoplasmosis, as well as improved strategies for diagnosis and therapy.

In conclusion, we describe herein a single-reaction, internally controlled, B1-Rep529 dual-target *T. gondii* real-time PCR assay for the diagnosis of ocular toxoplasmosis. This single-reaction, dual-target design maximises inclusivity and sensitivity, without loss of specificity.
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